Comparable stake leader
BlackRock, Inc.
SEC ownership of Elevance Health, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001156039.
Disclosed value leader
BlackRock, Inc.
Comparable rows
50/50
Latest evidence
17 Jul 2026
- Public ticker
- ELV on NYSE
- Parsed ownership sources
-
13D/G, 13F, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
BlackRock, Inc.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
BlackRock, Inc.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
17 Jul 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001156039
- Issuer location
- Indianapolis, IN
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Elevance Health, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
BlackRock, Inc.
Disclosed value leader
BlackRock, Inc.
Comparable rows
50/50
Latest evidence
17 Jul 2026
13D/G
13F
3/4/5
Lead comparable stake: 7.8%
13D/G row: BlackRock, Inc.
Showing 1-8 of 50 holder rows.
Quick read
BlackRock, Inc. leads the comparable SEC ownership view at 7.8%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens BlackRock, Inc.'s linked filing trail.
Comparable ownership
Top 5
BlackRock, Inc.
7.8%
VANGUARD CAPITAL MANAGEMENT LLC
7.1%
Lewis Hay III
0.01%
Ramiro G. Peru
0%
Robert L. Dixon Jr.
0%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| BlackRock, Inc. |
13D/G
13F
Company
|
7.8%
|
$7,319,395,282
17,694,658 shares
|
$0 | 31 Mar 2025 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13D/G
13F
Vanguard Capital Management · Company
|
7.1%
|
$4,860,008,326
16,601,224 shares
|
$0 | 31 Mar 2026 |
| Lewis Hay III |
3/4/5
Director
|
0.01%
|
$3,533,492
12,070 shares
|
— | 13 May 2026 |
| Ramiro G. Peru |
3/4/5
Director
|
0%
|
$3,992,873
10,908 shares
|
+$366,050 | 17 Jul 2026 |
| Robert L. Dixon Jr. |
3/4/5
Director
|
0%
|
$4,312,599
10,734 shares
|
-$60,667 | 11 Jun 2026 |
| R. Kerry Clark |
3/4/5
Director
|
0%
|
$3,987,586
9,640 shares
|
— | 14 May 2025 |
| Ryan M. Schneider |
3/4/5
Director
|
0%
|
$2,096,968
7,163 shares
|
— | 13 May 2026 |
| Antonio F. Neri |
3/4/5
Director
|
0%
|
$1,606,612
5,488 shares
|
— | 13 May 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to buying over the last 12 months. Net value: +$867,675.
Buys
$2,612,380
Insiders: 4
Sells
$1,744,705
Insiders: 4
Net
+$867,675
Shares: +2,652
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 7,925
Shares: 5,273
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 3,725 | 2,051 | $1,368,280 | $826,625 | +$541,655 |
| 3-6 | 3,000 | 3,222 | $869,520 | $918,079 | -$48,559 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 1,200 | 0 | $374,580 | $0 | +$374,580 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 28 reporting-owner rows connected to Elevance Health, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
28
Largest Forms 3/4/5 holder
Gail Boudreaux
Net 12M change
+$867,676
Latest report
17 Jul 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Gail Boudreaux | President and CEO, Director | $63,353,365 | +$1,002,230 | +1.6% | Mixed | 17 Jul 2026 |
| John E. Gallina | EVP & Chief Financial Officer | $30,619,225 | Mixed | 01 Mar 2023 | ||
| Gloria M. Mccarthy | EVP & Chief Administrative Off | $24,714,003 | Mixed | 24 Mar 2023 | ||
| Julie A. Hill | Director | $14,997,534 | Mixed | 20 May 2021 | ||
| Felicia F. Norwood | EVP &Chief Health Benefits Ofr | $12,826,249 | Mixed | 02 Mar 2026 | ||
| Mark Kaye Power | Evp & Cfo | $10,580,219 | Mixed | 02 Mar 2026 | ||
| Peter D. Haytaian | EVP & Pres Carelon & CarelonRx | $8,990,065 | Mixed | 02 Mar 2026 | ||
| Prakash R. Patel | EVP & President, DBG | $8,278,843 | Mixed | 04 Sep 2021 | ||
| Leah Stark | Evp & Chro | $5,959,517 | Mixed | 30 Dec 2021 | ||
| Blair Williams Todt | Evp, Clo & Cao | $5,807,854 | Mixed | 01 Mar 2024 | ||
| Elizabeth E. Tallett | Director | $5,481,810 | Mixed | 15 May 2024 | ||
| Ratnakar Lavu | EVP & Chief Digital Info Ofr | $5,333,207 | Mixed | 02 Mar 2026 | ||
| Robert L. Dixon Jr. | Director | $4,312,599 | -$60,667 | -1.4% | Filing P/S | 11 Jun 2026 |
| Ramiro G. Peru | Director | $3,992,873 | +$366,050 | +10% | Filing P/S | 17 Jul 2026 |
| R. Kerry Clark | Director | $3,987,586 | Mixed | 14 May 2025 | ||
| Lewis Hay III | Director | $3,533,492 | Mixed | 13 May 2026 | ||
| Charles Morgan Kendrick Jr. | EVP & President, Commercial | $3,359,491 | -$910,604 | -21% | Filing P/S | 06 Mar 2026 |
| Erin M. Wessling | EVP & Chief Legal Officer | $2,502,964 | Mixed | 02 Mar 2026 | ||
| Jeffrey D. Alter | EVP, IngenioRx & Anthem Health | $2,453,862 | Mixed | 01 Oct 2021 | ||
| Ryan R. Craig | EVP & Chief HR Officer | $2,204,088 | Mixed | 02 Mar 2026 |
Recent insider transactions for Elevance Health, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Ramiro G. Peru | ELV | Common Stock | Purchase | 10.1% | $366,050 | $366.05 | 1,000 | 10,908 | 17 Jul 2026 | Direct |
| Gail Boudreaux | ELV | Common Stock | Purchase | 1.61% | $1,002,230 | $367.79 | 2,725 | 171,976 | 17 Jul 2026 | Direct |
| Ronald W. Penczek | ELV | Common Stock | Sale | -8.98% | $148,766 | $403.16 | -369 | 3,740 | 12 Jun 2026 | Direct |
| Robert L. Dixon Jr. | ELV | Common Stock | Sale | -1.39% | $60,667 | $401.77 | -151 | 10,734 | 11 Jun 2026 | Direct |
| Ronald W. Penczek | ELV | Common Stock | Sale | -27.2% | $617,192 | $403.13 | -1,531 | 4,109 | 19 May 2026 | Direct |
| Ronald W. Penczek | ELV | Common Stock | Options Exercise | 37.3% | 1,531 | 5,640 | 19 May 2026 | Direct | ||
| Ronald W. Penczek | ELV | Employee Stock Option (Right to Buy) | Options Exercise | -100% | -1,531 | 0 | 19 May 2026 | Direct | ||
| D. Strable Soethout | ELV | Common Stock | Award | 34.2% | 563 | 2,209 | 13 May 2026 | Direct | ||
| Amy W. Schulman | ELV | Common Stock | Award | 258.3% | 563 | 781 | 13 May 2026 | Direct | ||
| Ryan M. Schneider | ELV | Common Stock | Award | 8.53% | 563 | 7,163 | 13 May 2026 | Direct | ||
| Ramiro G. Peru | ELV | Common Stock | Award | 6.02% | 563 | 9,908 | 13 May 2026 | Direct | ||
| Antonio F. Neri | ELV | Common Stock | Award | 11.4% | 563 | 5,488 | 13 May 2026 | Direct | ||
| Bahija Jallal | ELV | Common Stock | Award | 11.8% | 563 | 5,351 | 13 May 2026 | Direct | ||
| Lewis Hay III | ELV | Common Stock | Award | 4.89% | 563 | 12,070 | 13 May 2026 | Direct | ||
| Robert L. Dixon Jr. | ELV | Common Stock | Award | 5.45% | 563 | 10,885 | 13 May 2026 | Direct | ||
| Susan D. DeVore | ELV | Common Stock | Award | 16.1% | 563 | 4,065 | 13 May 2026 | Direct | ||
| Steven H. Collis | ELV | Common Stock | Award | 15.5% | 563 | 4,202 | 13 May 2026 | Direct | ||
| Amy W. Schulman | ELV | Common Stock | Sale | -10.7% | $7,475 | $287.50 | -26 | 218 | 12 Mar 2026 | Direct |
| Charles Morgan Kendrick Jr. | ELV | Common Stock | Sale | -21.3% | $910,604 | $284.92 | -3,196 | 11,791 | 06 Mar 2026 | Direct |
| Steven H. Collis | ELV | Common Stock | Purchase | 469.5% | $869,520 | $289.84 | 3,000 | 3,639 | 05 Mar 2026 | Direct |
| Ronald W. Penczek | ELV | Common Stock | Tax liability | -0.89% | -37 | 4,099 | 03 Mar 2026 | Direct | ||
| Erin M. Wessling | ELV | Common Stock | Tax liability | -5.22% | -417 | 7,579 | 03 Mar 2026 | Direct | ||
| Ryan R. Craig | ELV | Common Stock | Tax liability | -4.43% | -309 | 6,674 | 03 Mar 2026 | Direct | ||
| Felicia F. Norwood | ELV | Common Stock | Tax liability | -1.26% | -496 | 38,838 | 03 Mar 2026 | Direct | ||
| Ratnakar Lavu | ELV | Common Stock | Tax liability | -1.36% | -222 | 16,149 | 03 Mar 2026 | Direct | ||
| Charles Morgan Kendrick Jr. | ELV | Common Stock | Tax liability | -3.02% | -467 | 14,987 | 03 Mar 2026 | Direct | ||
| Peter D. Haytaian | ELV | Common Stock | Tax liability | -1.61% | -446 | 27,222 | 03 Mar 2026 | Direct | ||
| Mark Kaye | ELV | Common Stock | Tax liability | -1.09% | -353 | 32,037 | 03 Mar 2026 | Direct | ||
| Gail Boudreaux | ELV | Common Stock | Tax liability | -1.02% | -1,736 | 169,251 | 03 Mar 2026 | Direct | ||
| Ronald W. Penczek | ELV | Common Stock | Award | 137.3% | 2,393 | 4,136 | 02 Mar 2026 | Direct | ||
| Ronald W. Penczek | ELV | Common Stock | Tax liability | -6.99% | -131 | 1,743 | 02 Mar 2026 | Direct | ||
| Ronald W. Penczek | ELV | Employee Stock Option (Right to Buy) | Award | 1,677 | 1,677 | 02 Mar 2026 | Direct | |||
| Erin M. Wessling | ELV | Common Stock | Award | 59.3% | 2,976 | 7,996 | 02 Mar 2026 | Direct | ||
| Erin M. Wessling | ELV | Employee Stock Option (Right to Buy) | Award | 11,754 | 11,754 | 02 Mar 2026 | Direct | |||
| Ryan R. Craig | ELV | Common Stock | Award | 74.3% | 2,976 | 6,983 | 02 Mar 2026 | Direct | ||
| Ryan R. Craig | ELV | Common Stock | Tax liability | -0.62% | -25 | 4,007 | 02 Mar 2026 | Direct | ||
| Ryan R. Craig | ELV | Employee Stock Option (Right to Buy) | Award | 11,754 | 11,754 | 02 Mar 2026 | Direct | |||
| Felicia F. Norwood | ELV | Common Stock | Award | 28.9% | 8,816 | 39,334 | 02 Mar 2026 | Direct | ||
| Felicia F. Norwood | ELV | Common Stock | Tax liability | -4.45% | -1,421 | 30,518 | 02 Mar 2026 | Direct | ||
| Felicia F. Norwood | ELV | Employee Stock Option (Right to Buy) | Award | 23,512 | 23,512 | 02 Mar 2026 | Direct | |||
| Ratnakar Lavu | ELV | Common Stock | Award | 266.4% | 11,903 | 16,371 | 02 Mar 2026 | Direct | ||
| Ratnakar Lavu | ELV | Common Stock | Tax liability | -6.59% | -315 | 4,468 | 02 Mar 2026 | Direct | ||
| Ratnakar Lavu | ELV | Employee Stock Option (Right to Buy) | Award | 20,152 | 20,152 | 02 Mar 2026 | Direct | |||
| Charles Morgan Kendrick Jr. | ELV | Common Stock | Award | 73.5% | 6,549 | 15,454 | 02 Mar 2026 | Direct | ||
| Charles Morgan Kendrick Jr. | ELV | Common Stock | Tax liability | -12% | -1,211 | 8,905 | 02 Mar 2026 | Direct | ||
| Charles Morgan Kendrick Jr. | ELV | Employee Stock Option (Right to Buy) | Award | 15,870 | 15,870 | 02 Mar 2026 | Direct | |||
| Peter D. Haytaian | ELV | Common Stock | Award | 11.6% | 2,865 | 27,668 | 02 Mar 2026 | Direct | ||
| Peter D. Haytaian | ELV | Common Stock | Tax liability | -4.62% | -1,201 | 24,803 | 02 Mar 2026 | Direct | ||
| Mark Kaye | ELV | Common Stock | Award | 104.9% | 16,579 | 32,390 | 02 Mar 2026 | Direct | ||
| Mark Kaye | ELV | Common Stock | Tax liability | -1.69% | -271 | 15,811 | 02 Mar 2026 | Direct |
* marks a reported price that did not pass the local price check.